Cite
HARVARD Citation
Fan, Y. et al. (2019). Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway. Cancer biology & therapy. 20 (5), pp. 617-632. [Online].